Home/Filings/4/0001415889-25-014186
4//SEC Filing

Fitzpatrick Alexander A 4

Accession 0001415889-25-014186

CIK 0001671858other

Filed

May 21, 8:00 PM ET

Accepted

May 22, 5:00 PM ET

Size

9.0 KB

Accession

0001415889-25-014186

Insider Transaction Report

Form 4
Period: 2025-05-20
Fitzpatrick Alexander A
Chief Legal Officer
Transactions
  • Sale

    Common Stock

    2025-05-20$14.10/sh102,969$1,451,51389,613 total
  • Exercise/Conversion

    Common Stock

    2025-05-20$5.58/sh+100,000$558,000192,582 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-05-20100,000200,000 total
    Exercise: $5.58Exp: 2034-01-01Common Stock (100,000 underlying)
Footnotes (3)
  • [F1]Includes 3,355 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024.
  • [F2]The weighted average sale price for the transaction reported was $14.0966 and the range of prices were between $14.02 and $14.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F3]25% of the shares subject to the option vested on January 1, 2025, and the remaining shares will vest monthly thereafter over three years.

Issuer

ARS Pharmaceuticals, Inc.

CIK 0001671858

Entity typeother

Related Parties

1
  • filerCIK 0001398595

Filing Metadata

Form type
4
Filed
May 21, 8:00 PM ET
Accepted
May 22, 5:00 PM ET
Size
9.0 KB